Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in <i>NPM1</i>-mutant AMLJan Philipp Bewersdorf, Maximilian Stahl, Shai Shimony et al.|Blood Advances|2024Cited by 12
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in <i>IDH1</i>‐ or <i>IDH2</i>‐mutant newly diagnosed acute myeloid leukemia—A multicenter cohort studyJan Philipp Bewersdorf, Maximilian Stahl, Shai Shimony et al.|American Journal of Hematology|2024Cited by 9
Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid LeukemiaAlexandre Iat, Sylvain Garciaz, Jan Philipp Bewersdorf et al.|Blood|2024Cited by 2
Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategyGuillaume Berton, Geoffroy Venton, Robin Arcani et al.|Leukemia & lymphoma/Leukemia and lymphoma|2023Cited by 0
Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High‐Risk MDS Treated With Nucleoside AnalogsErwann Collomb, Geoffroy Venton, Laurent Bourguignon et al.|Hematological Oncology|2025Cited by 0